HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Dispute resolution guidance

This article was originally published in The Tan Sheet

Executive Summary

Drug manufacturers are allotted 30 days to ask for clarification of a disputed scientific or technical issue under a guidance for industry on formal dispute resolution published in the Federal Register Jan. 12. The draft guidance, which was released in 2003, allowed only a 10-day period (1"The Tan Sheet" Sept. 8, 2003, p. 11). If FDA's Dispute Resolution Panel deems the issue worthy of review, the new guidance states the panel must schedule a meeting within 90 days of the request, rather than the indefinite amount of time allowed in the draft. The guidance also notes that during the process, "a manufacturer may include relevant information that was not presented during the inspection," as long as FDA determines that a reasonable explanation is given on why it was not presented during the inspection...

You may also be interested in...



FDA Drug GMP Dispute Resolution Guidance Allows 10 Days For Objections

FDA's dispute resolution pilot will allow manufacturers 10 days to challenge FDA inspection findings

Cosmetic And Personal Care Trademark Review: 16 April

Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.

Health And Wellness Weekly Trademarks Review: 16 April

Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS099001

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel